Comprehensive Analysis of Hypoxia in Prostate Cancer: Diagnostic Markers and Prognostic Significance
Conditions
Prostate Cancer
Conditions: official terms
Prostatic Neoplasms
Study Type
Observational
Study Phase
Phase 3
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Intervention
Name: Pimonidazol
Type: Device
Overall Status
Recruiting
Summary
A single-center cohort study to identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancer
Detailed Description
1. To perform a large scale assessment of tissue hypoxia by pimonidazole and hypoxia marker gene expression in human prostate cancers

2. To characterize expression and hypoxia/HIF-responsiveness of myoglobin, cytoglobin, α-hemoglobin in prostate tumors and cell lines

3. To identify uni- and multivariate associations between marker gene expression and clinico-pathological parameters for the detection of robust and novel prognostic tools in prostate cancers
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Male
Criteria: Inclusion criteria:

- Patients with biopsy-proven adenocarcinoma of the prostate who are to be treated with radical prostatectomy at the Department of Urology, University Hospital of Zurich

- Written informed consent

Exclusion criteria:

- Metastatic prostate cancer

- Contraindications to the class of investigational product under study, e.g. known hypersensitivity or allergy to the investigational product

- Severe heart or lung disease

- Severe liver or kidney dysfunction

- Severe stridor

- Distant metastases

- Concurrent treatment for other malignant disease

- Prior hormonal therapy or radiotherapy
Location
University Hospital Zürich
Zurich, Switzerland
Status: Recruiting
Contact: Michael Müntener, MD - 0041 44 255 11 11 - michael.muentener@usz.ch
Start Date
August 2010
Completion Date
August 2020
Sponsors
University of Zurich
Source
University of Zurich
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page